Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergsk.com
Press releases
Get the latest updates from Press releases directly as they happen.
Follow now 453 followers
Latest posts
Last updated 3 days ago
New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade
3 days ago
End-of-trial data show 79.7% efficacy in participants aged 50 years and over...
EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments
3 days ago
GSK has announced positive results from the pivotal EAGLE-1 phase III trial...
GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA
4 days ago
Prescription Drug User Fee Act action date set by FDA for 14...
Positive RUBY phase III data show potential for Jemperli (dostarlimab) combinations in more patients with primary advanced or recurrent endometrial cancer
about 1 month ago
Only immuno-oncology combination to show statistically significant and clinically meaningful overall survival...
GSK announces positive results from DREAMM-8 phase III trial for Blenrep versus standard of care combination in relapsed/refractory multiple myeloma
about 1 month ago
Trial unblinded early at an interim analysis based on Independent Data Monitoring...
ViiV Healthcare announces interim data at CROI indicating superior efficacy of long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) compared to daily oral therapy in individuals living with HIV who have adherence challenges
about 1 month ago
The data were presented by the Advancing Clinical Therapeutics Globally for HIV/AIDS...
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses
about 2 months ago
GSK announced the company’s first step towards delivering ultra long-acting injectable HIV...
GSK announces Dr Jeannie Lee to join the Board as Non-Executive Director
about 2 months ago
GSK plc (LSE/NYSE: GSK) has today announced that Dr Jeannie Lee has...
Statement: Zantac (ranitidine) litigation
about 2 months ago
GSK plc (LSE/NYSE: GSK) today confirmed it has reached a confidential settlement...
ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV
about 2 months ago
Key abstracts to be presented at CROI 2024 by ViiV Healthcare and...
GSK announces positive headline results from EAGLE-1 phase III trial for gepotidacin in uncomplicated urogenital gonorrhoea (GC)
about 2 months ago
EAGLE-1 trial met its primary efficacy endpoint.
LATITUDE phase III interim trial data indicates ViiV Healthcare’s long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) has superior efficacy compared to daily therapy in individuals living with HIV who have adherence challenges
about 2 months ago
Full data set to be presented at an upcoming scientific conference.